Compare VLRS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | DBVT |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | Mexico | France |
| Employees | 7098 | 90 |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.4M | 948.8M |
| IPO Year | N/A | 2014 |
| Metric | VLRS | DBVT |
|---|---|---|
| Price | $8.74 | $17.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $9.16 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 524.0K | 258.4K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $13.96 | $35.04 |
| Revenue Next Year | $12.62 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $4.17 | $8.50 |
| 52 Week High | $10.80 | $26.19 |
| Indicator | VLRS | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 43.01 |
| Support Level | $8.59 | $16.49 |
| Resistance Level | $9.81 | $17.42 |
| Average True Range (ATR) | 0.38 | 0.94 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 98.13 | 38.02 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.